Study to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Rising Doses of BI 187004 CL

Boehringer Ingelheim

Status and phase: Completed; Phase 1

Conditions: Healthy

Treatments: Drug: Placebo to BI 187004 CL; Drug: BI 187004 CL

Study type: Interventional

Funder types: Industry

Identifiers

NCT01587417

2011-006183-45 (EudraCT Number)

1307.1

Details and patient eligibility

About

To investigate safety, tolerability, pharmacokinetics including dose proportionality, and pharmacodynamics of BI 187004 CL within a predefined dose range

Enrollment: 72 patients

Sex: Male

Ages: 18 to 55 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

1. Healthy male subjects
2. overweight or obese

Exclusion criteria

1. Any relevant deviation from healthy conditions

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind

---

72 participants in 2 patient groups, including a placebo group

BI 187004 CL

Experimental group

Description:

1 single dose per subject as oral solution

Treatment:

Drug: BI 187004 CL

Placebo to BI 187004 CL

Placebo Comparator group

Description:

1 single dose per subject as oral solution

Treatment:

Drug: Placebo to BI 187004 CL